Atopic Dermatitis (AD) is a inflammatory skin disease affecting approximately 10% of adults worldwide, with cases on the rise. While treatments for AD have improved in recent years, researchers are committed to further advancing therapies for people with mild to severe AD through clinical trails.
Study participation provides a chance to recieve new or previously unavailable procedures, at no cost.
Throughout the study you will be closely evaluated to ensure that the treatment received meet the highest scientific and medical standards.
3A’s researchers and staff have been carefully selected for their certifications and ability to preform study related procedures and exceptional patient care.
Participating in a clinical study is always voluntary (your choice). You can stop taking part in the study at any time without consequences to your usual medical care.
